EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, BMYMP: Bristol-Myers Squibb Co.

22 Dec 2025
LAST:

900.0

CHANGE:
 10.00		OPEN:
900.0		HIGH:
900.0		ASK:
0.0		VOLUME:
100
CHG(%):
1.10		PREV:
910.0		LOW:
900.0		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Dec 25900.0900.0900.0900.0100
19 Dec 25910.0910.0910.0910.0100
18 Dec 25936.8936.8910.0910.0100
15 Dec 25900.0900.0781.0900.0100
12 Dec 25891.0891.0881.1881.1100
05 Dec 25894.0894.0850.0892.0100
04 Dec 25878.0878.0878.0878.0100

PROFILE

Name:Bristol-Myers Squibb Co.
About:Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
CUSIP:110122207
CIK:0000014272
ISIN:US1101222073
LEI:HLYYNH7UQUORYSJQCN42

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:3,333.33 
DivYield:0.00 
Div/Share:1.59 

TECHNICAL INDICATORS

MA5:900.220.0%
MA10:882.951.9%
MA20:828.378.6%
MA50:799.3512.6%
MA100:863.684.2%
STO9:61.98
STO14:73.10
RSI14:71.98 
WPR14:-9.09 
MTM14:70.00
ROC14:0.08 
ATR:42.17 
Week High:936.804.1%
Week Low:781.0015.2%
Month High:936.804.1%
Month Low:751.00
Volatility:26.69